Durvalumab and Tremelimumab for Liver Cancer
Durvalumab and Tremelimumab have emerged as a groundbreaking immunotherapy duo, offering promising outcomes for advanced liver cancer, particularly unresectable hepatocellular carcinoma. With FDA approval and impressive survival rates, this combination marks a pivotal advancement in cancer treatment. Explore the mechanisms, clinical outcomes, safety profiles, and transformative role of these therapies in modern oncology. Durvalumab and […]
3 minute read